Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $545,772 - $952,529
14,695 New
14,695 $879,000
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $2.39 Million - $2.91 Million
31,186 New
31,186 $2.84 Million
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $142,475 - $201,126
3,295 Added 5.87%
59,465 $3.07 Million
Q3 2022

Nov 15, 2022

BUY
$44.76 - $69.66 $2.51 Million - $3.91 Million
56,170 New
56,170 $3.83 Million
Q2 2022

Aug 15, 2022

SELL
$35.07 - $59.21 $3.65 Million - $6.16 Million
-104,067 Closed
0 $0
Q1 2022

May 18, 2022

BUY
$35.46 - $54.12 $3.21 Million - $4.9 Million
90,576 Added 671.38%
104,067 $5.72 Million
Q4 2021

Feb 14, 2022

SELL
$30.74 - $49.16 $8.33 Million - $13.3 Million
-271,009 Reduced 95.26%
13,491 $640,000
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $7.47 Million - $16.6 Million
238,000 Added 511.83%
284,500 $9.56 Million
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $1.33 Million - $2.11 Million
32,500 Added 232.14%
46,500 $2.94 Million
Q1 2021

May 17, 2021

SELL
$40.8 - $57.39 $297,840 - $418,947
-7,300 Reduced 34.27%
14,000 $600,000
Q4 2020

Feb 16, 2021

BUY
$30.79 - $57.2 $655,827 - $1.22 Million
21,300 New
21,300 $1.22 Million
Q3 2020

Nov 12, 2020

SELL
$25.89 - $33.65 $220,065 - $286,025
-8,500 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$24.8 - $38.49 $3.61 Million - $5.6 Million
-145,500 Reduced 94.48%
8,500 $277,000
Q1 2020

May 14, 2020

BUY
$17.91 - $44.33 $2.47 Million - $6.12 Million
138,000 Added 862.5%
154,000 $4.13 Million
Q3 2019

Nov 14, 2019

BUY
$24.09 - $32.18 $385,440 - $514,880
16,000 New
16,000 $355,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.29B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Nomura Holdings Inc Portfolio

Follow Nomura Holdings Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Holdings Inc with notifications on news.